Composition with effects of reducing blood sugar and regulating blood fat and application thereof

Abstract

The invention relates to the technical field of functional food, in particular to a composition with the effects of reducing blood sugar and regulating blood fat and application of the composition. The invention provides a composition with the effects of reducing blood sugar and regulating blood fat, the composition comprises a cyclocarya paliurus triterpenoic acid compound and a selenoprotein additive, and the effect is optimal when the mass ratio of ursolic acid to oleanolic acid to betulinic acid to arjiurolic acid in the cyclocarya paliurus triterpenoic acid compound is optimized to be 1: 3.21: 3.37: 0.74 through a response surface experiment. According to the invention, the cyclocarya paliurus triterpene component and the selenium food nutrition enhancer are used at the same time, so that the cyclocarya paliurus selenium food nutrition enhancer can reduce blood sugar, regulate blood fat and increase the antioxidant capacity of the body, also has the functions of inhibiting postprandial blood sugar rise, relieving insulin resistance and protecting liver islet, and can meet the selenium intake of 50-200 micrograms per day of adults recommended by Chinese Nutrition Association; the health-care food can be used as a novel functional food to be applied to prevention and health care of sub-health people with hyperglycemia and hyperlipidemia.

Description

[0001] This invention is a divisional application. The original application was entitled "A composition having hypoglycemic and lipid-regulating effects and its application." The application number is 202310592095.X, and the application date is May 24, 2023.

[0002] A composition with hypoglycemic and lipid-regulating effects and its application. Technical Field

[0003] This invention relates to the field of functional food technology, and in particular to a composition having hypoglycemic and lipid-regulating effects and its application. Background Technology

[0004] Diabetes mellitus (DM) is a chronic metabolic disorder. Statistics show that in 2014, a significant number of adults worldwide had diabetes, with 90% suffering from type 2 diabetes (T2DM). Type 2 diabetes is characterized by insulin resistance leading to hyperglycemia and insufficient insulin secretion from pancreatic beta cells. Increasing evidence suggests a link between T2DM and obesity, as well as diseases affecting the liver, heart, and kidneys. Treatment for type 2 diabetes requires a comprehensive approach, including management of hyperglycemia and obesity, and prevention of diabetic complications. However, currently available antidiabetic drugs have limited efficacy and / or safety concerns; they only temporarily lower blood sugar levels, do not treat obesity, and do not prevent diabetic complications.

[0005] Statins are commonly used in clinical practice to regulate blood lipids. Statins are cholesterol biosynthesis enzyme inhibitors and are currently the most widely used class of lipid-regulating drugs in clinical practice. They are the main drugs for treating hypercholesterolemia. However, these drugs can cause gastrointestinal reactions and headaches, and may cause muscle toxicity when used in combination with other lipid-lowering drugs.

[0006] As can be seen from the above, treating diabetes with Western medicine has significant side effects on patients' bodies.

[0007] *Cyclocaryapaliurus (Batal) Ijinskaja*, also known as the copper coin tree or sweet tea tree, is a tree belonging to the genus *Cyclocaryapaliurus* in the family Juglandaceae. It is a unique, second-class protected monotypic plant in China. *Cyclocaryapaliurus* is a medicinal and edible plant with great development potential. Researchers have isolated over a hundred organic chemical components from its leaves, including phenols, polysaccharides, and triterpenoids, among other pharmacologically active ingredients. Triterpenoids are the most important and frequently isolated chemical components from *Cyclocaryapaliurus* leaves, and are also one of the sources of new compounds in *Cyclocaryapaliurus*. They are important active components in *Cyclocaryapaliurus* for its anti-hyperglycemic and lipid-regulating effects. Studies have shown the effect of the triterpenic acid-rich fraction (CPT) of *Cyclocaryapaliurus* on insulin resistance induced by a high-fat diet in C57BL / 6 mice, indicating that CPT can significantly improve insulin resistance induced by a high-fat diet in mice. Other studies have shown that the ethanol extract of *Cyclocaryapaliurus*, rich in the aforementioned three pentacyclic triterpenoids, possesses anti-hyperlipidemia activity. Triterpene acid extract from *Cyclocarya paliurus* is a highly promising active ingredient for improving glucose and lipid metabolism disorders. However, due to differences in growing region, leaf harvesting season, and extraction methods, the active ingredients in *Cyclocarya paliurus* triterpene acid extract are complex and their content is difficult to control, making it difficult to determine the main active components and their mechanism of action unclear, thus limiting its practical application in health foods and other fields. Studies have shown that ursolic acid (UA), oleanolic acid (OA), betulinic acid (BA), and ajangalamic acid (AC) are the main active components of *Cyclocarya paliurus* triterpenes, and numerous in vitro and in vivo studies have also confirmed the hypoglycemic effects of these triterpene acids. Applying these four active ingredients together in health products can regulate glucose and lipid metabolism through multiple pathways. However, determining the optimal combination to achieve good hypoglycemic and lipid-lowering effects while minimizing side effects is a crucial problem to be solved in developing highly effective hypoglycemic and lipid-regulating foods.

[0008] Selenium (Se) is a vital trace element for humans and animals, exerting various biological functions primarily through selenoproteins, especially selenoenases. Currently, organic selenium fortifiers used in nutritional foods include selenoproteins, selenium-enriched edible fungi powder, selenized carrageenan, selenium-enriched yeast, and selenium-methylselenocysteine ​​(MSC). These organic selenium forms possess excellent antioxidant, immune-regulating, anti-tumor, and cardiovascular disease-treating properties. Since daily consumption of natural food ingredients cannot meet the body's daily selenium intake requirements, developing selenium-enriched foods using selenium food fortifiers has become an important measure to meet the selenium needs of Chinese residents.

[0009] In modern life, abnormal glucose metabolism causes immense suffering and severely restricts daily dietary choices. Research on hypoglycemic products containing Eucommia ulmoides extract has revealed that existing products primarily lower blood sugar, offering only a single, limited effect; their inhibitory effect on hyperlipidemia caused by diabetes is not significant. Therefore, finding a functional food that is highly safe for human health and can, to some extent, help lower blood sugar while regulating blood lipids is urgently needed. Summary of the Invention

[0010] To address the aforementioned problems, this invention provides a composition with hypoglycemic and lipid-regulating effects, and its application. The composition of this invention can effectively lower blood sugar and regulate blood lipids, and is highly safe for human use.

[0011] To achieve the above objectives, the present invention provides the following technical solution:

[0012] The present invention provides a composition having the effects of lowering blood sugar and regulating blood lipids. Each 100g of the composition comprises the following components: 0.1-9g of Cyclocarya paliurus triterpenic acid compound, 0.05-6mg of selenoprotein additive and the balance being water.

[0013] Preferably, the *Cyclocarya paliurus* triterpene acid complex includes three or more of the following: ursolic acid, oleanolic acid, betulinic acid, alpinic acid, β-boswellic acid, corosolic acid, and maseriic acid.

[0014] Preferably, when the *Cyclocarya paliurus* triterpene acid compound includes ursolic acid, oleanolic acid, and betulinic acid, the mass ratio of ursolic acid, oleanolic acid, and betulinic acid is 1:1 to 3.5:1 to 3.5.

[0015] When the *Cyclocarya paliurus* triterpene acid compound includes ursolic acid, oleanolic acid, betulinic acid and ajangalamic acid, the mass ratio of ursolic acid, oleanolic acid, betulinic acid and ajangalamic acid is 1-3:1-3.5:1-3.5:0.5-1.

[0016] Preferably, the selenoprotein additive includes L-selenomethylselenocysteine, selenium-enriched yeast, or tea selenoprotein.

[0017] This invention provides a method for preparing the composition described in the above technical solution, comprising the following steps:

[0018] The compound of triterpenoid acids from Eucommia ulmoides, selenoprotein additives, and some water were mixed and stirred to obtain the primary product.

[0019] The primary product is mixed with the remaining water to obtain the composition.

[0020] Preferably, the mixing temperature is 30°C.

[0021] Preferably, the stirring method is magnetic stirring; the stirring time is 1 to 3 hours, and the stirring speed is 1000 to 3000 rpm.

[0022] This invention provides the application of the composition described in the above technical solution in the preparation of functional foods with hypoglycemic and lipid-regulating effects.

[0023] This invention provides a functional food product that lowers blood sugar and regulates blood lipids, wherein the effective ingredients include those described in the above technical solution.

[0024] Preferably, the dosage form of the functional food is tablets, capsules, dry suspensions, solutions, or suspensions.

[0025] The beneficial effects of this invention are as follows:

[0026] (1) The ursolic acid, oleanolic acid, betulinic acid, alpinic acid, β-boswellic acid, corosolic acid and maseriic acid of this invention are high-purity active hypoglycemic and hypolipidemic components derived from Eucommia ulmoides.

[0027] (2) The components used in the compound of the present invention have a clear mechanism of action and significant efficacy, and can be used in combination with other effective components.

[0028] (3) The Qingqianliu triterpenic acid composition obtained in this invention has clear components and fixed content, and has the functions of lowering blood sugar, regulating blood lipids, inhibiting postprandial blood sugar rise, relieving insulin resistance, and protecting liver and pancreatic function.

[0029] (4) Compared with traditional Cyclocarya paliurus extract, this invention selects active ingredients with a certain content and clear efficacy for lowering blood sugar and regulating blood lipids, and combines them with selenoproteins such as tea selenoproteins, selenium-enriched yeast, and selenomethyl selenocysteine, so that the active ingredients of Cyclocarya paliurus can exert antioxidant effects at the same time, and increase the protective effect on the kidneys, liver and pancreas.

[0030] (5) This invention selects representative active components of *Cyclocarya paliurus* triterpenoids, including ursolic acid, oleanolic acid, betulinic acid, and ajangalamic acid. Response surface methodology is used to determine the ratio of these components, resulting in a novel functional food for the prevention and health maintenance of individuals with hyperglycemia, hyperlipidemia, and sub-health conditions. This food is further compounded with MSCs to supplement selenium while simultaneously lowering blood sugar and regulating blood lipids, thereby enhancing selenium's antioxidant effects. This achieves synergistic effects of different mechanisms of action, such as lowering blood sugar, regulating blood lipids, antioxidation, and improving immunity, providing a new approach for the research and development of novel high-performance health foods. Therefore, this invention combines *Cyclocarya paliurus* triterpenoids with selenium-enriched food fortifiers. While lowering blood sugar and regulating blood lipids, it also increases the body's antioxidant capacity, inhibits postprandial blood sugar rise, alleviates insulin resistance, and protects the liver and pancreas. Furthermore, it meets the recommended daily selenium intake of 50–200 μg for adults by the Chinese Nutrition Society, maintaining human health, and exhibits high safety for the human body. The components used in the composition of this invention have a clear mechanism of action and significant efficacy, and can be used in combination with other components that have other effects. Furthermore, the composition of this invention can simultaneously inhibit α-glucosidase, α-amylase, and pancreatic lipase, with the best inhibitory effect on α-glucosidase. Attached Figure Description

[0031] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the accompanying drawings used in the embodiments will be briefly described below.

[0032] Figure 1 The inhibitory effects of Examples 1-2 and Comparative Examples 1-3 on pancreatic lipase were observed.

[0033] Figure 2 The inhibitory effects of Examples 1-2, Comparative Examples 1-2 and Comparative Example 4 on α-glucosidase were shown.

[0034] Figure 3 The inhibitory effects of Examples 1-2, Comparative Examples 1-2, and Comparative Example 4 on α-amylase are shown.

[0035] Figure 4 The effects of Examples 1, 3, 4 and Comparative Example 5 on glucose consumption in palmitic acid-induced insulin-resistant cells were investigated. Compared with the normal group, ***p<0.001; compared with the model group, #p<0.05, ##p<0.01, ###p<0.001; compared with Example 3, &&p<0.05.

[0036] Figure 5 The effects of Example 1-low, Example 1-high, Comparative Example 1-low, Comparative Example 1-high, and Comparative Example 5 on liver structure, fat, and fibrosis in diabetic mice;

[0037] Figure 6 The effects of Example 1-Low, Example 1-High, Comparative Example 1-Low, Comparative Example 1-High, and Comparative Example 5 on glucose tolerance in diabetic mice were investigated. Compared with the normal group, ***p<0.001; compared with the model group, #p<0.05, ##p<0.01, ###p<0.001; compared with Comparative Example 5, @p<0.05.

[0038] Figure 7 The effects of Example 1-Low, Example 1-High, Comparative Example 1-Low, Comparative Example 1-High, and Comparative Example 5 on insulin tolerance in diabetic mice were investigated. Compared with the normal group, ***p<0.001; compared with the model group, #p<0.05, ##p<0.01, ###p<0.001; compared with Comparative Example 1-High, &p<0.05.

[0039] Figure 8 The effects of Example 1-Low, Example 1-High, Comparative Example 1-Low, Comparative Example 1-High, and Comparative Example 5 on serum cholesterol and triglyceride levels in diabetic mice were investigated. Compared with the normal group, ***p<0.01; compared with the model group, #p<0.05, ##p<0.01, ###p<0.001; compared with Comparative Example 1-High, &p<0.05; compared with Comparative Example 5, @p<0.05.

[0040] Figure 9 The effects of Example 1-Low, Example 1-High, Comparative Example 1-Low, Comparative Example 1-High, and Comparative Example 5 on serum low-density lipoprotein and high-density lipoprotein levels in diabetic mice were investigated. Compared with the normal group, ***p<0.001; compared with the model group, #p<0.05, ##p<0.01, ###p<0.001; compared with Comparative Example 1-High, &p<0.05; compared with Comparative Example 5, @p<0.05.

[0041] Figure 10 The effects of Example 1-Low, Example 1-High, Comparative Example 1-Low, Comparative Example 1-High, and Comparative Example 5 on serum TNF-α and IL-6 levels in diabetic mice were investigated. Compared with the normal group, ***p<0.01; compared with the model group, #p<0.05, ##p<0.01, ###p<0.001; compared with Comparative Example 1-High, &p<0.05.

[0042] Figure 11The effects of Example 1-Low, Example 1-High, Comparative Example 1-Low, Comparative Example 1-High, and Comparative Example 5 on serum SOD, CAT, and GSH-Px levels in diabetic mice were investigated. Compared with the normal group, ***p<0.001; compared with the model group, #p<0.05, ##p<0.01, ###p<0.001; compared with Comparative Example 1-High, &p<0.05; compared with Comparative Example 5, @p<0.05.

[0043] Figure 12 The glucose consumption of HepG2 cells after treatment with 1–10 μg / mL L-selenomethylselenocysteine ​​dilutions for 24 h was measured (n = 4, Mean ± SD; compared with Control, **p < 0.01).

[0044] Figure 13 The inhibitory effects of Examples 1-2, Examples 9-10, and Comparative Example 3 on pancreatic lipase were observed.

[0045] Figure 14 The inhibitory effects of Examples 1-2, Examples 9-10 and Comparative Example 4 on α-glucosidase are shown. Detailed Implementation

[0046] This invention provides a composition with hypoglycemic and lipid-regulating effects, wherein each 100g of the composition comprises the following components: 0.1-9g of *Cyclocarya paliurus* triterpenic acid compound, 0.05-6mg of selenoprotein additive, and the balance being water. In this invention, 1g of the composition is equal to 1mL of the composition.

[0047] In this invention, the *Cyclocarya paliurus* triterpene acid complex preferably includes any three or more of the following: ursolic acid, oleanolic acid, betulinic acid, algonyl palmitic acid, β-boswellic acid, corosolic acid, and maseriic acid, but is not limited to ursolic acid, oleanolic acid, betulinic acid, algonyl palmitic acid, β-boswellic acid, corosolic acid, and maseriic acid; more preferably, it includes ursolic acid, oleanolic acid, betulinic acid, and algonyl palmitic acid.

[0048] When the *Cyclocarya paliurus* triterpene acid complex includes ursolic acid, oleanolic acid, and betulinic acid, the mass ratio of ursolic acid, oleanolic acid, and betulinic acid is preferably 1:1 to 3.5:1 to 3.5, more preferably 1:3.21:3.37, or 1:1:1, or 1:3:3. When the *Cyclocarya paliurus* triterpene acid complex includes ursolic acid, oleanolic acid, betulinic acid, and ajangalalic acid, the mass ratio of ursolic acid, oleanolic acid, betulinic acid, and ajangalalic acid is preferably 1 to 3:1 to 3.5:1 to 3.5:0.5 to 1, more preferably 1:3.21:3.37:0.74; or 1:1:1:1, or 1:3:1:1, or 3:1:1:1. In this invention, ursolic acid can be abbreviated as UA, oleanolic acid can be abbreviated as OA, betulinic acid can be abbreviated as BA, alpinic acid can be abbreviated as AC, and maseriic acid is also called hawthorn acid.

[0049] This invention does not impose any special limitations on the source of the ursolic acid, oleanolic acid, betulinic acid, ajanglamic acid, β-boswellic acid, corosolic acid, and maslid acid, which can be obtained by means of conventional purchase by those skilled in the art. In specific embodiments of this invention, the ursolic acid, oleanolic acid, betulinic acid, ajanglamic acid, β-boswellic acid, coroswellic acid, and maslid acid are preferably purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. The preferred product number for ursolic acid is U107243, for oleanolic acid is O110088, for betulinic acid is B432746, for ajanglamic acid is A170471, for β-boswellic acid is B139119, for coroswellic acid is D135631, and for maslid acid is M138840.

[0050] This invention utilizes ursolic acid, oleanolic acid, betulinic acid, and alginic acid as high-purity active hypoglycemic and lipid-regulating components derived from *Cyclocarya paliurus*, exhibiting high purity. In the *Cyclocarya paliurus* triterpene acid complex described in this invention, ursolic acid, oleanolic acid, and betulinic acid can promote glucose absorption and uptake, increase endogenous glycogen synthesis, and reduce glycogen breakdown. They can also improve the symptoms of STZ- and high-fat diet-induced type 2 diabetes mice by promoting phosphorylation of key molecules in the phosphatidylinositol / protein kinase B / glycogen synthase kinase 3β (PI3K / Akt / GSK3β) signaling pathway. Alginic acid can significantly enhance the glucose uptake capacity of C2C12 myotube cells and 3T3-L1 adipocytes under insulin stimulation. β-Boswellic acid, corosolic acid, and maseriic acid possess antitumor, hypoglycemic, anti-inflammatory, and antioxidant effects. The Qingqianliu triterpenic acid compound of the present invention has a clear composition and fixed content, and has the effects of lowering blood sugar and regulating blood lipids. It also has the functions of inhibiting the rise of postprandial blood sugar, relieving insulin resistance, and protecting the liver and pancreas.

[0051] This invention combines ursolic acid, oleanolic acid, betulinic acid, and ajanglamic acid, which exhibit excellent inhibitory effects on glucose and lipid metabolism enzyme activity in vitro (enzyme inhibition experiment). It can inhibit postprandial blood glucose elevation and lipid absorption, further enhancing the hypoglycemic and lipid-regulating effects. It also inhibits lipase, α-amylase, and α-glucosidase activities, making it particularly suitable for people with type 2 diabetes. Furthermore, it regulates glucose and lipid metabolism through multiple pathways, and the specific ratios between the components ensure good hypoglycemic and lipid-lowering effects with minimal side effects.

[0052] The selenoprotein additives of this invention preferably include L-selenomethylselenocysteine, selenium-enriched yeast, or tea selenoprotein, but are not limited to L-selenomethylselenocysteine, selenium-enriched yeast, and tea selenoprotein, and more preferably include L-selenomethylselenocysteine. This invention does not specifically limit the source of the L-selenomethylselenocysteine, selenium-enriched yeast, and tea selenoprotein; they can be obtained through conventional purchase by those skilled in the art. In a specific embodiment of this invention, the L-selenomethylselenocysteine ​​is preferably purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., with the preferred product number S16277; the selenium-enriched yeast is preferably purchased from Henan Rongshen Chemical Co., Ltd., with the preferred product number 5321456; and the tea selenoprotein is preferably purchased from Henan Kangzhiwang Biotechnology Co., Ltd., with the preferred product number 9012-76-4.

[0053] The selenoprotein additive in each 100g of the composition of the present invention is preferably 0.1-5mg, and more preferably 0.5-4mg. The selenoprotein additive of the present invention can also be called a selenium food fortifier.

[0054] When the selenoprotein additive preferably includes L-selenomethylselenocysteine, the mass of L-selenomethylselenocysteine ​​is preferably 0.05-1 mg, more preferably 0.5-1 mg, and even more preferably 0.5 mg per 100 g of the composition.

[0055] When the selenoprotein additive preferably includes selenium-enriched yeast, the mass of the selenium-enriched yeast is preferably 0.05 to 1 mg, more preferably 0.5 to 1 mg, and even more preferably 0.5 mg per 100 g of the composition.

[0056] When the selenoprotein additive preferably includes tea selenoprotein, the mass of the tea selenoprotein is preferably 0.05-1 mg, more preferably 0.5-1 mg, and even more preferably 0.5 mg per 100 g of the composition.

[0057] The L-selenomethylselenocysteine ​​in the selenoprotein additive of this invention has anti-tumor effects and can alleviate oxidative stress and metal homeostasis imbalance in Alzheimer's disease mouse models. It can improve neuropathology and cognitive deficits. Selenium-enriched yeast and tea selenoproteins, as food-derived organic selenium, can prevent and treat selenium deficiency diseases and supplement selenium. L-selenomethylselenocysteine ​​is called a third-generation selenium supplement. It can be used as a selenium supplement for selenium-deficient people, as well as a preventive and interventional agent for various chronic diseases such as diabetes, cancer, and liver disease. Selenized carrageenan has the effect of protecting the liver and preventing and treating liver diseases. Supplementing healthy people with selenized carrageenan can reduce the incidence of hepatitis A and B. Taking selenized carrageenan supplements can improve the body's immunity.

[0058] When the *Cyclocarya paliurus* triterpene acid compound includes ursolic acid, oleanolic acid, and betulinic acid, and the selenoprotein additive includes L-selenomethylselenocysteine, the composition preferably comprises the following raw materials by mass per 100g of the composition: 3.21g oleanolic acid, 3.37g betulinic acid, and 0.5mg L-selenomethylselenocysteine; or 1.0g ursolic acid, 1.0g oleanolic acid, 1.0g betulinic acid, and 0.5mg L-selenomethylselenocysteine; or 1.0g ursolic acid, 3.0g oleanolic acid, 3.0g betulinic acid, and 0.5mg L-selenomethylselenocysteine.

[0059] When the *Cyclocarya paliurus* triterpene acid compound includes ursolic acid, oleanolic acid, betulinic acid, and ajanglamic acid, and the selenoprotein additive includes L-selenomethylselenocysteine, the composition preferably comprises the following raw materials by mass per 100g of the composition: 0.1–1.5g ursolic acid, 0.1–4g oleanolic acid, 0.1–4g betulinic acid, 0.1–1.0g ajanglamic acid, and 0.05–1mg L-selenomethylselenocysteine; more preferably, 1.0g ursolic acid, 3.21g oleanolic acid, 3.37g betulinic acid, 0.74g ajanglamic acid, and 0.5mg L-selenomethylselenocysteine.

[0060] When the *Cyclocarya paliurus* triterpene acid compound includes ursolic acid, oleanolic acid, betulinic acid, and ajanglamic acid, and the selenium protein additive includes selenium-enriched yeast, the composition preferably comprises the following raw materials by mass per 100g of the composition: 0.1–1.5g ursolic acid, 0.1–4g oleanolic acid, 0.1–4g betulinic acid, 0.1–1.0g ajanglamic acid, and 0.05–1mg selenium-enriched yeast; more preferably, 1.0g ursolic acid, 3.21g oleanolic acid, 3.37g betulinic acid, 0.74g ajanglamic acid, and 0.5mg selenium-enriched yeast.

[0061] When the *Cyclocarya paliurus* triterpene acid compound includes ursolic acid, oleanolic acid, betulinic acid, and ajanglamic acid, and the selenoprotein additive includes tea selenoprotein, the composition preferably comprises the following raw materials by mass per 100g of the composition: 0.1–1.5g ursolic acid, 0.1–4g oleanolic acid, 0.1–4g betulinic acid, 0.1–1.0g ajanglamic acid, and 0.05–1mg tea selenoprotein, more preferably 1.0g ursolic acid, 3.21g oleanolic acid, 3.37g betulinic acid, 0.74g ajanglamic acid, and 0.5mg tea selenoprotein.

[0062] The *Cyclocarya paliurus* triterpenic acid used in this invention is a high-purity plant-derived hypoglycemic active ingredient with a clearly defined structure and active ingredients, possessing the ability to improve glucose and lipid metabolism disorders. The selenoprotein additive compensates for the insufficient selenium content in the above components and, compared to inorganic selenium, exhibits better bioavailability and safety, and is more readily absorbed by the intestines. Compared to traditional *Cyclocarya paliurus* extracts, this invention creatively combines the *Cyclocarya paliurus* triterpenic acid complex and the selenoprotein additive, allowing the active ingredients of *Cyclocarya paliurus* to simultaneously exert antioxidant effects, increasing protection for the kidneys, liver, and pancreas, while simultaneously meeting the Chinese Nutrition Society's recommended daily selenium intake of 50-200 μg for adults, maintaining human health. It synergistically lowers blood sugar and blood lipids in patients, achieving a more superior hypoglycemic effect, and also enhances the body's antioxidant capacity, increasing protection for the liver and pancreas while lowering blood sugar. The combination of *Cyclocarya paliurus* triterpenic acid and the selenoprotein additive improves diabetes and its complications from three aspects: regulating blood lipids, lowering blood sugar, and increasing antioxidant activity; moreover, it has few side effects on the human body.

[0063] This invention provides a method for preparing the composition described in the above technical solution, comprising the following steps: mixing a *Cyclocarya paliurus* triterpene acid complex, a selenoprotein additive, and a portion of water, and stirring to obtain a primary product; mixing the primary product with the remaining water to obtain the composition. In this invention, the mixing temperature is preferably 30°C; the stirring method is preferably magnetic stirring; the stirring time is preferably 1–3 hours, more preferably 2 hours; and the stirring speed is preferably 1000–3000 rpm, more preferably 1000 rpm. This invention mixes the *Cyclocarya paliurus* triterpene acid complex and the selenoprotein additive under preheating conditions, and begins magnetic stirring when they dissolve in water without obvious clumping. This ensures that the *Cyclocarya paliurus* triterpene acid complex and the selenoprotein additive are uniformly dispersed in water without clumping.

[0064] The present invention also preferably provides a method of consuming the above-mentioned composition, comprising mixing the composition with health products or oral liquids to obtain a mixture that is ready for consumption. In the present invention, based on 100g of the mixture, the mixture preferably includes 8.354g of *Cyclocarya paliurus* triterpenic acid compound and 0.5mg of selenoprotein additive, more preferably including 1.0g of ursolic acid, 3.21g of oleanolic acid, 3.37g of betulinic acid, 0.74g of ajanglamic acid, and 0.5mg of L-selenomethylselenocysteine. The method of consumption described in the present invention involves mixing the composition with other foods for immediate use, without the need for further processing, thus demonstrating the advantage of the convenient application of the composition.

[0065] Based on the above advantages, this invention provides the application of the composition described in the above technical solution in the preparation of functional foods with hypoglycemic and lipid-regulating effects. In this invention, the functional food preferably includes health foods, health drinks, or nutritional oral liquids, but is not limited to these categories.

[0066] This invention provides a functional food product that lowers blood sugar and regulates blood lipids. The effective ingredients of the functional food product include the composition described in the above-mentioned technical solution. In this invention, the dosage form of the functional food product is preferably tablets, capsules, dry suspensions, solutions, or suspensions.

[0067] To further illustrate the present invention, the composition with hypoglycemic and lipid-regulating effects provided by the present invention and its application are described in detail below with reference to the accompanying drawings and embodiments, but these should not be construed as limiting the scope of protection of the present invention.

Claims

1. A method for preparing a functional food, characterized in that, Includes the following steps: The compound of triterpenoid acids from Eucommia ulmoides, selenoprotein additives, and some water were mixed and stirred to obtain the primary product. The primary product is mixed with the remaining water to obtain the functional food. The Qingqianliu triterpenic acid compound includes at least three of the following: ursolic acid, oleanolic acid, betulinic acid, alpinic acid, β-boswellic acid, corosolic acid, and maseriic acid. When the *Cyclocarya paliurus* triterpene acid compound includes ursolic acid, oleanolic acid, and betulinic acid, the mass ratio of ursolic acid, oleanolic acid, and betulinic acid is 1:1 to 3.5:1 to 3.

5.

2. A functional food, characterized in that, It is prepared by the preparation method described in claim 1.

3. The application of the functional food as described in claim 2 in the preparation of hypoglycemic products.

4. The application of the functional food as described in claim 2 in the preparation of lipid-regulating products.

Images